Related Experiment Video
Updated: Oct 12, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Anticoagulation after stroke: persistent uncertainties
Bernhard M Siepen1,2, David J Seiffge1, Urs Fischer1,3
1Department of Neurology, Inselspital University Hospital Bern and University of Bern.
Insights
Direct oral anticoagulants (DOACs) are crucial for preventing stroke in atrial fibrillation. Current research addresses uncertainties in timing, stroke causes, and bleeding risks, with ongoing trials promising improved patient management.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Direct oral anticoagulants (DOACs) are standard for stroke prevention in nonvalvular atrial fibrillation.
- Significant uncertainties persist regarding optimal DOAC use in specific clinical scenarios.
Purpose of the Study:
- To review current dilemmas in DOAC therapy for stroke prevention.
- To discuss uncertainties based on recent clinical studies and ongoing trials.
Main Methods:
- Review of selected studies focusing on DOAC therapy in atrial fibrillation and stroke.
- Analysis of recent findings from randomized controlled trials and risk stratification scores.
Main Results:
- Optimal timing for DOAC initiation post-ischemic stroke remains undetermined.
- Stroke recurrence despite anticoagulation has varied causes, requiring etiological work-up.
- DOACs showed no benefit in unselected embolic stroke of undetermined source (ESUS) patients; trials are investigating ESUS subgroups.
- The MICON score aids in stratifying intracranial hemorrhage risk.
Conclusions:
- Significant uncertainties persist in managing anticoagulation for stroke patients.
- Ongoing clinical trials are expected to provide new data for improved patient care.
Purpose Of Review:
Direct oral anticoagulants (DOAC) are the mainstay of anticoagulant therapy for stroke prevention in patients with nonvalvular atrial fibrillation. Persistent uncertainties remain in different areas, and this review discusses current dilemmas based on selected studies.
Recent Findings:
Optimal timing of DOAC initiation after a recent ischaemic stroke in patients with atrial fibrillation is currently unknown and subject of ongoing randomized controlled trials. Ischaemic stroke despite anticoagulant therapy in patients with atrial fibrillation is frequent, constitutes heterogeneous causes (competing stroke cause, medication error and cardioembolism despite anticoagulation) and optimal treatment is currently unknown. Thorough etiological work-up is justified. Recent randomized controlled trials found no beneficial effect of DOAC therapy in unselected patients with embolic stroke of undetermined source (ESUS). Currently ongoing trials targeting subgroup of ESUS patients with additional atrial cardiopathy will provide novel data. Cerebral mircobleeds combined in a novel risk score (MICON score) provide good predictive value to stratify the risk of intracranial haemorrhage in patients taking anticoagulants. Use of DOAC after intracerebral haemorrhage in patients with atrial fibrillation is subject of ongoing trials.
Summary:
There are still significant uncertainties in anticoagulant management in patients with stroke. Ongoing trials will soon provide novel data to improve management of these patients.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Venous Thrombosis IV: Nursing Management
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

